title: Human tumor models in the severe combined immune deficient (scid) mouse.
abstract: OBJECTIVE
  To test a number of established human tumor cell lines and early passage breast cancer (UACC2150) and melanoma cells (UACC1273) for growth in the scid mouse and the tumors' response to conventional chemotherapeutic drugs.
  
  
  METHODS
  Established melanoma (A375, C81-61), colon (SW480), lung (A549), lymphomoblastoid leukemia (LCL-B), promyelocytic leukemia (HL60), prostate (PC-3, DU145), and breast (MCF7) cell lines were injected at subcutaneous (s.c.), intraperitoneal (i.p.), or mammary fat pad (MFP) sites. Tumor volume growth curves and survival curves were established for the various tumor cell lines. Carmustine (BCNU), cisplatin (CDDP), cyclophosphamide (CPA), doxorubicin, dacarbazine (DTIC), tamoxifen and vincristine were injected s.c. or i.p.. The chemotherapeutic drug effects on tumor volumes and survival were determined.
  
  
  RESULTS
  Tumor growth occurred with each cell type. After i.p. injection, 90% mortality occurred within 26 to 60 days except for the early passage melanoma cell line UACC1273 with which mortality occurred within approximately 90 days. In the MCF7 breast model, treatment with tamoxifen (P < 0.001) and CPA (P < 0.0001) resulted in significant tumor growth delay compared with control groups. BCNU and CDDP resulted in significant tumor growth delays relative to control in SW480 colon cancer (P < 0.0014) and A375 melanoma (P < 0.0001) models, respectively. CPA and doxorubicin improved survival in the HL60 leukemia model (P = 0.0018).
  
  
  CONCLUSIONS
  These scid mouse human tumor models appear to reflect the clinical situation in that clinically active chemotherapeutic drugs are similarly active in the scid mouse models. Therefore, the scid mouse models may be useful for testing new chemotherapeutic agents against various human cancer types.
authors.affiliation: Department of Medicine, Arizona Cancer Center, University of Arizona College of Medicine, Tucson 85724, USA.
authors.forename: G D
authors.initials: GD
authors.lastname: Paine-Murrieta
authors.forename: C W
authors.initials: CW
authors.lastname: Taylor
authors.forename: R A
authors.initials: RA
authors.lastname: Curtis
authors.forename: M H
authors.initials: MH
authors.lastname: Lopez
authors.forename: R T
authors.initials: RT
authors.lastname: Dorr
authors.forename: C S
authors.initials: CS
authors.lastname: Johnson
authors.forename: C Y
authors.initials: CY
authors.lastname: Funk
authors.forename: F
authors.initials: F
authors.lastname: Thompson
authors.forename: E M
authors.initials: EM
authors.lastname: Hersh
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D004195:Disease Models, Animal; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D051379:Mice; D016513:Mice, SCID; D008875:Middle Aged; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D016511:Severe Combined Immunodeficiency / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D015996:Survival Rate; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents